A modelling group convened by the World Health Organization and UNAIDS has estimated that if efforts are not made to mitigate and overcome interruptions in health services and supplies during the COVID-19 pandemic, a six-month disruption of antiretroviral therapy could lead to more than 500 000 extra deaths from AIDS-related illnesses, including

South Africa is one of the countries with the highest burden of tuberculosis (TB). According to the World Health Organisation (WHO) statistics, 322,000 TB cases reported in South Africa in 2017.

The bi-directional relationship between poverty and tuberculosis (TB) is well established. Poverty aggravates material disadvantage, social exclusion, discrimination in participation across a wide range of socio-economic and behavioural activities along with undernutrition, overcrowding, lack of access to healthcare and other social determinants of health.

Social network data of tuberculosis (TB) patients could explain the source and pattern of disease spread. A review of the published literature highlights that social network data could identify hidden social or epidemiological links among TB patients and improved TB case finding.

One of the first multicenter randomized trials was the British Medical Research Council (MRC) streptomycin trial. From the first meeting of the special committee to “plan trials of streptomycin in tuberculosis” in September, 1946, the primary trial results from 107 participants followed for 12 months were published in the British Medical Journal two years later in October, 1948. Although treatment with a single drug was subsequently shown to be inadequate because of the generation of drug resistance, the results of the trial changed clinical practice.

The objective of the study was to review policies on management of latent tuberculosis infection in countries with low and high burdens of tuberculosis.

Original Source

Of patients with multidrug-resistant tuberculosis (MDR TB), <50% complete treatment. Most treatment failures for patients with MDR TB are due to death during TB treatment. We sought to determine the proportion of deaths during MDR TB treatment attributable to TB itself. We used a structured verbal autopsy tool to interview family members of patients who died during MDR TB treatment in India during January–December 2016.

The existing treatment regime against tuberculosis is not adequate, and novel therapeutic interventions are required to target Mycobacterium tuberculosis (Mtb) pathogenesis. We report Pranlukast (PRK) as a novel allosteric inhibitor of Mtb's arginine biosynthetic enzyme, Ornithine acetyltransferase (MtArgJ). PRK treatment remarkably abates the survival of free as well as macrophage‐internalized Mtb, and shows enhanced efficacy in combination with standard‐of‐care drugs.

The tuberculosis vaccine bacillus Calmette-Guérin (BCG) has heterologous beneficial effects against non-related infections. The basis of these effects has been poorly explored in humans.

The risk of tuberculosis outbreaks among people fleeing hardship for refuge in Europe is heightened. We describe the cross-border European response to an outbreak of multidrug-resistant tuberculosis among patients from the Horn of Africa and Sudan.

Original Source